Fig. 2From: Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemiaSchematic representation of the mechanism of action of Omacetaxine. Oncogene transcription leads to mRNA translation that induce oncoprotein synthesis. Omacetaxine reduces BCR-ABL1 expression levels by blocking the ribosome t-RNA aminoacil acceptor site that results in a protein elongation arrestBack to article page